Posts by: Patricia Inacio, PhD

News

Nanobiotix is planning to conduct nine Phase 1/2 clinical trials in collaboration with the University of Texas MD Anderson Cancer Center to study the company’s investigational compound NBTXR3. The trials, which will ... Read more

January 29, 2019January 29, 2019

Keytruda Reduces Risk of Death in Some Patients with Advanced Esophageal Cancer, Study Shows

News

Second-line treatment with Keytruda (pembrolizumab) significantly extends the lives of advanced esophageal cancer and esophagogastric junction carcinoma patients whose tumors are positive for the PD-L1 factor, a Phase 3 clinical ... Read more

January 23, 2019January 23, 2019

FDA to Review Tecentriq Triple Combo as First-Line Treatment for Certain NSCLC Patients

News

The U.S. Food and Drug Administration will review Genentech‘s Tecentriq (atezolizumab), in combination with chemotherapy medications Abraxane (nab-paclitaxel) and carboplatin, as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC), the company ... Read more

January 22, 2019January 22, 2019

First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Cancer

News

A Phase 3 clinical trial evaluating the immune checkpoint inhibitor Tyvyt (sintilimab injection), in combination with the chemotherapies Taxol (paclitaxel) and Platinol (cisplatin), as a first-line treatment for esophageal squamous cell carcinoma has ... Read more

January 18, 2019

New Collaboration Aims to Identify Biomarkers of Bladder Cancer Progression, Immunotherapy Response

News

A new collaboration between GeneCentric Therapeutics and researchers at the University of North Carolina at Chapel Hill is aimed at further understanding bladder cancer patients’ responses to immunotherapies. Moreover, researchers hope ... Read more

January 11, 2019

Keytruda Receives Five New Approvals in Japan, Including 3 Expanded Uses for Lung Cancer

News

Keytruda (pembrolizumab) has simultaneously received five new approvals in Japan, including four expanded uses — three for advanced non-small cell lung cancer (NSCLC) and one for melanoma — and a new indication ... Read more

January 2, 2019January 2, 2019

Celyad’s Donor-derived CAR T-cell Therapy Begins Testing in Colorectal Cancer

News

A Phase 1 trial evaluating Celyad’s CYAD-101 — a donor-derived CAR T-cell product — to treat metastatic colorectal cancer has dosed its first patient, the company announced. The trial, ... Read more

December 14, 2018

AMG 330 Immunotherapy Shows Promise in Relapsed or Refractory Acute Myeloid Leukemia

News

A Phase 1 clinical trial assessing Amgen’s immunotherapy AMG 330 showed promising results in acute myeloid leukemia (AML) patients who received at least one prior treatment, the company announced. AMG 330, given at 120 and 240 ... Read more

December 11, 2018

FDA Approves Tecentriq Combo as Initial Treatment for Select Patients with Advanced NSCLC

News

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab), in combination with Avastin (bevacizumab) and the chemotherapies Taxol (paclitaxel) and carboplatin, for a first-line treatment of certain patients with metastatic non-squamous ... Read more

Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Nanobiotix Plans Nine NBTXR3 Clinical Trials for Six Cancer Types

Keytruda Reduces Risk of Death in Some Patients with Advanced Esophageal Cancer, Study Shows

FDA to Review Tecentriq Triple Combo as First-Line Treatment for Certain NSCLC Patients

First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Cancer

New Collaboration Aims to Identify Biomarkers of Bladder Cancer Progression, Immunotherapy Response

Keytruda Receives Five New Approvals in Japan, Including 3 Expanded Uses for Lung Cancer

Top 10 Immuno-Oncology Stories of 2018

Celyad’s Donor-derived CAR T-cell Therapy Begins Testing in Colorectal Cancer

AMG 330 Immunotherapy Shows Promise in Relapsed or Refractory Acute Myeloid Leukemia

FDA Approves Tecentriq Combo as Initial Treatment for Select Patients with Advanced NSCLC

Pin It on Pinterest